Pierre Fabre claims to now be “aligned” with U.S. regulators on the path forward for a twice-rejected treatment. Elsewhere, Argenx swapped CEOs and Blackstone made a $250 million biotech investment.
An article from
News roundup
Pierre Fabre claims to now be “aligned” with U.S. regulators on the path forward for a twice-rejected treatment. Elsewhere, Argenx swapped CEOs and Blackstone made a $250 million biotech investment.
Published May 8, 2026
Getty Images
Astellas treatment offers new hope to a devastated rare disease community
FDA to reconsider treatment for rare cancer after its surprise rejection
FDA revisits a rare cancer treatment it rejected a few months ago
The biotech news you need to read today
Are analysts too quick to gloss over Lilly's liver case?
UCB to acquire maker of antibody treatments for autoimmune diseases
Novo Nordisk's less-bad news on its Wegovy pill boosts earnings and share price
Even at a meeting in Rome, FDA shifts are top of mind for gene therapy field
Targeted Protein Degradation and Novel Modalities: Getting on the Frontline
Hims' sales miss as telehealth competition grows
